Clinical trials: Esophagogastric Junction
Gastric Cancer
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or…
- Trial name
- NCT05327231
- Testing
- IN10018, Docetaxel
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance in Gastric and GEJ Adenocarcinoma
Surgical resection remains the only curative option for resectable gastric cancer, but perioperative FLOT chemotherapy is associated with substantial rates of chemoresistance and recurrence, largely driven by marked tumor…
- Trial name
- GASTROIMMUNE (NCT07692477)
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Overall Response Rate
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
- Trial name
- NCT06277024
- Testing
- Combination of Cardonizumab with Lenvatinib and SOX regimen
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.
- Trial name
- NCT04781686
- Testing
- Camrelizumab, Apatinib Mesylate, S1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhou Fuxiang
Gastroesophageal-junction Cancer, Esophageal Cancer
Registry for Esophageal and Gastroesophageal Junction Cancer
The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer/GEJ cancer.
- Trial name
- NCT06558786
- Testing
- EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophagogastric Junction Disorder
Idiopathic Esophagogastric Junction Outflow Obstruction
This study compares two treatments for Idiopathic Esophagogastric Junction Outflow Obstruction: pneumatic dilation compared with expectant management, on symptoms and liquid barium emptying exams.
- Trial name
- NCT04096703
- Testing
- Pneumatic dilation
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Gastric/Gastroesophageal Junction Adenocarcinoma
Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma
A single-arm, Phase II clinical study protocol of Apatolimab Tovolimab in combination with regorafenib and chemotherapy as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
- Trial name
- NCT07148427
- Testing
- Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression
- Trial name
- NCT06939452
- Testing
- anlotinib +TQB2450 + Oxaliplatin+S-1
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Yongxu Jia
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic…
- Trial name
- NCT07221149
- Testing
- Pumitamig, Folfox, Capox
- Where
- 161 sites in United States, Argentina and 18 more
- Volunteers
- 690 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
This phase II trial is studying how well arsenic trioxide works in treating patients with metastatic or unresectable cancer of the esophagus or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
- Trial name
- NCT00061958
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Gastric Cancer, Stomach Cancer
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.
- Conditions
- Gastric Cancer, Stomach Cancer, Esophageal Cancer
- Trial name
- NCT02689284
- Testing
- Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 95 people
- Sponsor
- MacroGenics
Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial
This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors.
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- PRECISE (NCT07439484)
- Testing
- Actigraphy, Biospecimen Collection, Educational Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00991952
- Testing
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
- Trial name
- NCT01253525
- Testing
- Ramucirumab (IMC-1121B ), Paclitaxel
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Gastric Adenocarcinoma
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric…
- Trial name
- NCT02862535
- Testing
- Andecaliximab, S-1, Cisplatin
- Where
- 3 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Gastrostomy, Gastric
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
- Conditions
- Gastrostomy, Gastric, GastroEsophageal Cancer
- Trial name
- NCT05205343
- Testing
- Standard of Care, Control Group
- Where
- 4 sites in United States, Japan and 1 more
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
The goal of this clinical research study is to learn if a combination of the investigational drug oxaliplatin with 5-Fluorouracil (5-FU) (given at the same time as radiation therapy) is as effective as a combination of these two…
- Trial name
- NCT00525915
- Testing
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.